CRBUCaribou Biosciences, Inc.

$186M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-41.6% YoY

Gross Profit

-$28M-1337.8% margin

Operating Income

-$39M-1871.7% margin

Net Income

-$35M-1708.7% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+2.6%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$36M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$313M

Total Liabilities

$60M

Stockholders' Equity

$253M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$4M	-41.6%
Gross Profit	-$28M	$2M	-1854.2%
Operating Income	-$39M	-$37M	-3.8%
Net Income	-$35M	-$35M	-2.9%

Geographic Segments

UNITED STATES

$5M96%

Non-US

$197,0004%

CRBU Q4 2024 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena